FDA places clinical hold on BioMarin's Phase 1/2 gene therapy study in phenylketonuria

0
medium_image_1286971245.jpg

FDA places clinical hold on BioMarin's Phase 1/2 gene therapy study in phenylketonuria

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *